Publication:
Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes.

Simple item page
dc.contributor.authorGokcal, Elif
dc.contributor.authorPasi, Marco
dc.contributor.authorFisher, Marc
dc.contributor.authorGurol, M Edip
dc.date.accessioned2023-05-16T16:00:49Z
dc.date.available2023-05-16T16:00:49Z
dc.date.issued2018-02-05T21:00:00Z
dc.description.abstractThis review aims to help neurologists managing atrial fibrillation (AF) patients who had an ischemic stroke and/or with intracranial hemorrhage (ICH) markers, therefore at high embolic/hemorrhagic risks.
dc.description.abstractImplantable loop recorders have substantially improved the accuracy of AF detection. Recent research yielded a set of powerful neuroimaging markers that can stratify ICH risk. Direct oral anticoagulants (DOAC) are easier to use with a lower ICH risk than warfarin in a general AF population. Finally, the FDA-approved left atrial appendage closure (LAAC) with the WATCHMAN device provides an option without the need for life-long anticoagulation. In this review, we introduce the concept of preventing both ischemic and hemorrhagic strokes in AF patients through accurate AF diagnosis and stratification of both embolic and ICH risks. LAAC can be considered in patients at higher hemorrhagic risks while warfarin/DOAC use should be individualized in the majority of AF patients at a low risk of bleeding.
dc.identifier.pubmed29411147
dc.identifier.urihttps://hdl.handle.net/20.500.12645/38070
dc.language.isoen
dc.subjectAtrial fibrillation
dc.subjectIntracerebral hemorrhage
dc.subjectIschemic stroke
dc.subjectLeft atrial appendage closure
dc.titleAtrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes.
dspace.entity.typePublication
Files
Collections
Pubmed Ek Yayınlar